GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

GSK plc (NYSE: GSK) Q2 2025 Earnings Conference Call July 30, 2025 7:00 AM ET Company Participants Deborah Jayne Waterhouse - CEO of ViiV Healthcare & President of Global Health Emma Natasha ...

GSK has moved to shore up its R&D pipeline with a strategic-level partnering deal with China's Jiangsu Hengrui Pharma.

Elsewhere in the MASH space, GSK in May bet $2 billion to acquire Boston Pharmaceuticals’ efimosfermin alfa, an investigational FGF21 analog that works by helping to lower fat, easing inflammation and ...

Madrigal does have one notable challenger on its horizon, with GSK poised to enter the MASH arena in the next few years after it bought Boston Pharmaceuticals’ Phase III-ready efimosfermin alfa, an ...

Driven by exceptional growth in Specialty Medicines and Vaccines, GSK’s second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding ...